Drug Profile
Research programme: zinc finger protein-based therapeutics - Sangamo/LifeScan
Alternative Names: ZFN-based therapeutics - Sangamo Therapeutics/LifeScanLatest Information Update: 12 Jan 2017
Price :
$50
*
At a glance
- Originator Sangamo BioSciences
- Class Cell therapies; Gene therapies; Zinc finger DNA binding proteins
- Mechanism of Action Genetic transcription modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
- 07 Apr 2008 This research programme is ongoing